Prostate cancer genetic testing prognosis risk assessment system (Prostatype® testing system)

The world's leading

A global leader: Precision medical findings from the Nobel institution urology professor at the Karolinska Institute team for nearly 20 years
1. The global leader in genetic testing for prostate cancer prognostic risk assessment system
2. Use the world's only course of treatment as a real patient Reference risk assessment system
3. Research and development achievements of academicians of the Royal Swedish Academy of Engineering (IVA)
4. Combined genetic testing factors significantly improve the accuracy of prognostic scores
5. Revolutionarily provide more scientific treatment options for patients with prostate cancer

Prostate cancer clinical background

1. Prostate cancer is one of the highest incidence of male cancer in Western developed countries in Europe, America and Europe;
2. With the improvement of economic level and residents' living standards in China, its incidence rate is also rapidly increasing. It is expected that it will enter Chinese males within ten years The top three of malignant tumors;
3. Although the incidence of prostate cancer is high, not all cancer subtypes are malignant and fatal, and most prostate cancer subtypes (nearly 80%) are relatively benign rather than fatal;
4. Studies have shown that 7 out of 10 of them are over-treated or under-treated, mainly due to the low accuracy of clinical prognostic scores.
5. The survival rate of prostate cancer patients in developed countries is more than 98% over 5 years, while in China Terrible 50%.

Prostate cancer treatment in the world

Prostatype®

Our prostate cancer risk prognosis detection system
How does it improve forecast accuracy?
What clinical problems can be solved?

Testing process

Product advantages

1. The key technology involved in this project has applied for an international invention patent, which has been approved in Sweden, Japan, China and the United States.
2. Using the combination of the world's leading genetic technology and biological big data, revolutionaryly provide accurate personalized treatment programs for prostate patients, and greatly improve the accuracy of patient prognosis risk assessment.
3. This project is based on the advantages of Sweden's first and the most complete clinical samples and follow-up data in the world, and completely tracks the patient's entire process.
4. The database of this project is composed of 600 real cases, and the patient's clinical data and genetic test data are completely collected. The software that meets the clinical registration standards was developed using mathematical models and statistical analysis. The software's prostate cancer risk classification The algorithm and cancer risk index are globally unique and have passed CE certification.
5. This project is currently the only testing system in the world that does not need to send patient samples to a special laboratory for testing, and can be directly used in the clinic for doctors to use.
6. Prostatype can improve the accuracy of prognosis judgment of survival time by 25%, especially for patients with medium-risk patients who are most difficult to choose treatment options.

Prognostic system compared with European standards EAU and CARPA

Comparison of international mainstream products

Company name	Chundsell Medicals (Sweden)	Genomic Health (United States)	Myriad GeneDcs (United States)	MetamarksGeneDcs (United States)	Bostwick Laborator ies (United States)
product name	Prostatype®Test System	Oncotype Prostate DX	Prolaris	Promark	ProstaVysion
Detection gene	RNA expression levels of 4 related genes	17 related gene RNA expression levels	46 related gene RNA expression levels	8 related protein expression levels	3 related gene mutations
Gene type	Stem cell gene	Proliferation gene	Proliferation gene	Proliferation gene	Proliferation gene
Clinical application	Treatment and survival prognosis	Prognosis of treatment, refer to NCNN	Treatment prognosis, refer to CAPRA	Prognosis of treatment, refer to NCNN	No
Scientific verification	3 articles	2 articles	2 articles	3 articles	PTEN / ERG related reports
Laboratory type	Local molecular pathology experiment	CLIA Standardized Laboratory	CLIA Standardized Laboratory	CLIA Standardized Laboratory	CLIA Standardized Laboratory
Forecast period	2 days	7 days	7 days	7 days	7 days
Applied country	Sweden, Switzerland, Germany	United States, Germany, Switzerland	United States, Germany, Switzerland	United States	United States

Prognosis evaluation system service object

For the patient
1. Provide information for the patient before deciding whether to treat
2. Help the patient to participate in the formulation

For the urologist
1. Provide a more accurate treatment plan
2. Avoid overtreatment or undertreatment
3. Discuss the treatment plan for the patient Provide strong support

For pathologists
1. Balance the subjectivity of Gleason Index
2. Enhance pathological assessment information

Product Category

Prostate cancer genetic testing prognosis risk assessment system (Prostatype® testing system)

热烈欢迎百色市常务副市长石国怀、坪山区委书记陶永欣、区长李勇、副区长陈华平莅临我司考察

喜讯 | 我司获广东省科技进步二等奖

喜讯！深圳亿立方生物新冠试剂获CE认证

抗疫战役中诞生的先锋队-深圳市亿立方生物技术有限公司党支部

1.5 hours!ONE STEP screening of 18 respiratory pathogens！